OR WAIT null SECS
July 10, 2025
Article
Explore the transformative potential of MDMA-assisted therapy and psychedelics in treating PTSD and addiction, offering hope where traditional methods fail.
Transcend Therapeutics' TSND-201 gains FDA Breakthrough Therapy designation, offering new hope for rapid PTSD treatment with promising clinical trial results.
June 10, 2025
Video
At SLEEP 2025, Colvonen discussed RCT findings that showed VeNS significantly improved PTSD and insomnia symptoms, offering a scalable solution for patients awaiting 1-on-1 care.
June 09, 2025
May 31, 2025
Systematic review of 34 randomized trials finds EMDR most effective, though civilians were more likely than veterans to lose their PTSD diagnosis after treatment.
April 02, 2025
This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.
March 31, 2025
TSND-201 (methylone) met its primary endpoint in the phase 2 IMPACT-1 trial, showing rapid, significant PTSD symptom improvement with a good safety profile.
March 07, 2025
This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.
January 25, 2025
Women experience more severe early PTSD symptoms than men, with re-experiencing and avoidance clusters being strongest. Men showed stronger anxious arousal patterns.
December 29, 2024
This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.
